Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
May 7, 2021
Earnings Call Speaker Segments
Operator
operatorShayne Laidlaw from investor relations — you have the floor, go ahead.
Shayne Laidlaw
executiveThanks, Polly, and I appreciate everyone being here today as we go through Cronos Group's financial and business results for the first quarter of 2021. With me on the call are our President and Chief Executive Officer, Kurt Schmidt; our Chief Financial Officer, Jerry Barbato; our Executive Chairman, Mike Gorenstein; and our Executive Vice President of Legal and Regulatory Affairs, Xiuming Shum. This morning Cronos Group put out a news release announcing these financial results, and that release has been filed on our EDGAR and SEDAR profiles. You'll also find this information, along with the prepared remarks, posted on our website under investor relations. Before handing things over to Kurt, I want to remind everyone that what we discuss on this conference call will include forward-looking statements. Those statements rest on assumptions that carry risks and uncertainties, and those could make actual results differ materially from what the forward-looking statements project, including because of the factors laid out in the cautionary statement and risk factors contained in the company's earnings release and regulatory filings, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and any forward-looking statements made during this call are qualified in their entirety by those documents.
Shayne Laidlaw
executiveAlso, on today's call we might talk about some financial metrics that aren't recognized under U.S. generally accepted accounting principles, which the Securities and Exchange Commission calls non-GAAP measures. In our view, these non-GAAP measures help management with planning, forecasting, and evaluating business and financial performance, including how resources get allocated. You'll find reconciliations of these non-GAAP measures to the closest reported GAAP measures in our earnings press release furnished to the SEC, and that's available in the press room section of our website, thecronosgroup.com. Measures used by other issuers may not be comparable to these non-GAAP measures. I'd also like to mention that today we're holding this call from our respective remote locations. Because of that, brief delays, crosstalk, or minor technical issues could come up during this call. We thank you ahead of time for your patience and understanding. We'll now deliver prepared remarks, and after that we'll move to a question and answer session. With that, I'll hand things over to Cronos Group's President and Chief Executive Officer, Kurt Schmidt.
Kurt Schmidt
executiveThank you, Shayne. To kick off this call, I'd like to express my appreciation to the global team for the ongoing, tireless work they put in to make Cronos a leader in the markets where we compete. Even though the battle with COVID-19 is not entirely behind us and vaccine availability differs to varying degrees in the markets where we operate, I remain hopeful that we can find a route to a more normal life before long. We feel grateful to our team for the creativity and ingenuity they show in growing our business and pressing ahead, whatever the circumstances may be. Moving to our first quarter results, I'll begin by looking back at a few highlights from the quarter that underscore Cronos' dedication to building disruptive technology and innovation and to strengthening our capacity to compete — two of my main areas of focus for this year. On the innovation side, Cronos and Ginkgo Bioworks were named among the winners of Fast Company's prestigious 2021 Most Innovative Companies award in the Joint Ventures category. That is a well-regarded award that recognizes the significant and innovative work we are carrying out with our partners at Ginkgo. We are humbled by the recognition of the incredible work we are doing together.
Kurt Schmidt
executiveGinkgo remains central to the story we tell about innovation. Working jointly, we've managed to ferment CBG — one of the cannabinoids we're targeting — successfully at research scale, and we keep anticipating drawing on our R&D, innovation, and consumer insight teams to fuel development of differentiated product offerings. In April, most recently, Health Canada granted us our processing license for fermented cannabinoids at the facility we operate in Winnipeg, Manitoba — a major milestone for Cronos that underscores how strong our organization is across every function. Receipt of that license had been factored into our product calendar for this point in time, and we stay on schedule for commercialization on the timing we've already disclosed. With this technology and our world-class R&D and innovation teams, we anticipate pushing the cannabis industry forward, working to responsibly improve what consumers experience. This week we put out a significant commitment: our marketing code of conduct. As a company, we hold that people under the legal age of consumption ought not to be targeted within adult-use cannabis markets. We see plainly that standards are needed, and that's why we took the initiative to build our own marketing code, offering it as a resource for the industry and for policymakers. Every principle set out in that marketing code governs all marketing activities across all our brands worldwide.
Kurt Schmidt
executiveThis code reflects Cronos' dedication to responsible marketing standards. Cronos expects everyone from our leadership team to our external agencies to understand and adhere to these principles. Elevating industry practices is what our marketing code aims for, and it marks a significant step in that direction. We hope others in the industry will make similar commitments. As policymakers weigh how best to regulate a federally legal U.S. cannabis market, we believe these principles capture the kinds of policies our industry needs. Last month, we hit a new industry milestone by launching our Cronos Group Employees PAC. This PAC was created to support and educate legislators who are open to responsibly advancing legislation and regulation for CBD products, and also those working toward a well-regulated, safe, and legal federal cannabis market in the U.S. We strongly believe policymakers and regulators need to invest in approaches that support responsible adult consumption, limit consumer harm by curtailing the illicit market, and establish a legal, well-regulated federal framework for the U.S. cannabis industry. Creating this PAC is one step toward realizing that vision. With legalization efforts continuing throughout the U.S., we stay committed to being an integral part of the conversation. Our government affairs work bolsters our ability to compete globally, and we believe cannabis should be legal at the federal level, with a comprehensive and reasonable federal regulatory framework put in place for the industry.
Kurt Schmidt
executiveThrough our PAC contributions and the publication of our marketing code, we take pride in publicly backing responsible legalization initiatives within the United States. Although we're doing everything possible from a corporate standpoint to advance federal legalization in the U.S., Mike Gorenstein, serving as Executive Chairman, keeps collaborating with the Cronos team internally to assess a range of market opportunities. As our worldwide organization pursues parallel routes toward an organic entry strategy — supported by the extensive set of innovations we're developing at our PEACE NATURALS Center of Excellence in Stayner, Ontario, along with the substantial cannabinoid knowledge our research teams in Israel have acquired — we're confident that, with our balance sheet, current CBD infrastructure, and our strategic investor, we'll become a best-in-class cannabis company in the U.S. Now regarding the U.S. segment: near the conclusion of the first quarter, we started offering our Happy Dance brand at more than 550 Ulta Beauty stores across the U.S., and on ulta.com as well. We're happy with how things are going as we build momentum and mind share among Ulta consumers. Expanding our distribution capabilities marks a crucial next step in this brand's evolution, and we expect additional product launches to follow so that consumer variety grows throughout the year.
Kurt Schmidt
executiveBack in April, we shared some thrilling news regarding our Lord Jones brand. Lord Jones has, for the very first time since the brand began, rolled out a substantial marketing push combining several market activations — among them out-of-home advertising along with TV commercials across a variety of test markets throughout the U.S. Within its own niche, Lord Jones stands as a powerful brand. With this campaign, and all the resources we're throwing behind it, the brand's voice will grow even louder, dramatically broadening awareness with adult consumers. The initial feedback and reactions we've gotten from consumers and our retail partners have been favorable, and I'm eager to watch just how much this marketing campaign accomplishes for the brand through 2021 and beyond. Over the course of my career, I've built a handful of brands. Authenticity and a top-quality product are where it all begins, and those are things we definitely possess. What we need to do now is ensure people are aware of it, and that is precisely where the marketing effort plays its part. This investment of ours reaffirms how dedicated we are to backing the marketing work behind our core brand throughout every region. As I noted during our last call, building excellent cannabis brands right here at Cronos is among my objectives for this year. We're enthusiastic about this strong marketing plan for Lord Jones and can't wait to introduce this much-loved brand to additional consumers all over the U.S.
Kurt Schmidt
executiveWe’re lucky to have the means to establish Lord Jones as a robust brand in the CBD sector, creating brand awareness for upcoming line extensions into other parts of the cannabis industry. Performance in our rest-of-world segment—Canada in particular—took a hit from market dynamics tied to continuing COVID-19 restrictions and logistics problems caused by stay-at-home orders and the restrictions that followed across the country. Certain provincial stores faced prolonged lockdown measures and a shift back to curbside pickup and delivery, and that has weighed on sales growth. Once the weather in Canada gets warmer, curbside pickup becomes a smaller obstacle to growth than it is during the colder months. Recent data indicates the Canadian cannabis industry is climbing back from the low point of the first calendar quarter, which is an encouraging signal for growth ahead. That said, with the Canadian market still feeling the effects of the COVID-19 pandemic, we stay focused on execution and innovation in this key market, challenges notwithstanding. During the past quarter, our Canadian innovation and marketing teams have been hard at work bringing our pipeline to life—developing and commercializing new products that are slated for release in the weeks and months ahead.
Kurt Schmidt
executiveOur approach to product development is methodical: we understand what consumers need and then bring future products to market. Being first isn't necessarily what concerns us. Our focus is on being the best. I'm excited to share that in the coming weeks we will release a new edible product under the Spinach brand. While developing this product, we let deep consumer insights guide our decisions and drew on our strong R&D innovation teams to bring it to life. Our innovation group, made up of scientists, engineers, and experts from the CPG world, has put an incredible amount of time into this new product, which we think could lead the edible segment in the Canadian market. By taking a thoughtful, insights-first approach with this new product, we believe we'll deliver a brand that is truly unique and of high quality. As I said at the start of the year, building disruptive technology and innovation is vital for Cronos. We still believe that investing in innovation and research will unlock cannabis's full potential, helping us create standout products and giving us a long-term competitive advantage. Turning to Israel, the Israeli medical cannabis market keeps growing, both in patient count numbers, which are steadily increasing and have now surpassed 88,000 registered medical patients, and in the expansion of distribution, where more and more pharmacies are interested in selling medical cannabis to patients in Israel.
Kurt Schmidt
executiveAfter we signed that deal with Super-Pharm in February — Israel's biggest pharmacy chain, with more than 250 locations — we're really enthusiastic about expanding in this market that's changing so quickly. Within Israel, our PEACE NATURALS brand keeps building momentum in the flower and oil segments, and not long ago we brought pre-rolls to market under the PEACE NATURALS brands. From those, we've seen solid results right out of the gate. The strength of our team based in Israel continues to make an impression on me. I'm eager to see what they'll achieve over the rest of 2021. Even with a tough macro backdrop, I couldn't be prouder of the way our team pushed through the first quarter. As I consider the remainder of 2021, our plans excite me, along with what we're setting out to achieve together as a global team. With that, I'll hand the call to our Chief Financial Officer, Jerry Barbato.
Jerry Barbato
executiveThanks, Kurt, and good morning, everyone. Now to our financial results: the company posted consolidated net revenue of CAD 12.6 million in the first quarter of 2021, which is a 50% increase from the prior year period. The year-over-year revenue growth came mainly from expansion in the Canadian adult use cannabis market, sales in the Israeli medical market, and growth in our U.S. hemp-derived CBD business, partly offset by strategic price reductions taken in the second half of 2020 on various adult-use cannabis products in Canada. Consolidated gross loss for the first quarter of 2021 was CAD 3 million, which is a CAD 3.5 million decrease in losses from the first quarter of 2020. The improvement versus prior year was primarily driven by an increase in net revenue and a decline in spend due to brand development in the U.S. segment and an increase in R&D, driven by spending on product development and developing cannabinoid IP, partially offset by decreases in sales and marketing spend in the rest of world segment, gross loss, and general and administrative expenses. Turning to our reporting segments, in the rest of world segment, we reported net revenue in the first quarter of 2021 of CAD 10.2 million, a 63% increase from the prior year period.
Jerry Barbato
executiveWhen we look at the year-over-year revenue increase, the main drivers were ongoing expansion in Canada's adult use cannabis flower market along with gains in Israel's medical cannabis market. Those gains were partly offset by deliberate price cuts we made on assorted adult-use products in Canada during the second half of 2020, plus lower Canadian sales of cannabis extracts, which stemmed largely from provincial demand that kept fluctuating. For the rest of world segment in the first quarter of 2021, gross loss came to CAD 4.1 million — a CAD 3.4 million reduction in losses compared with the first quarter of 2020. That year-over-year improvement came mainly from higher revenue and fewer inventory write-downs. As we spend 2021 and beyond building an efficient global supply chain for our rest of world segment, we expect gross margin to keep fluctuating as prices and mix shift quarter-to-quarter. Adjusted EBITDA loss for the rest-of-world segment in the first quarter of 2021 totaled CAD 22.2 million, which is a CAD 6.8 million decrease in losses versus the first quarter of 2020. That gain was driven mainly by a smaller gross loss and lower general and administrative expenses, partly offset by higher research and development costs.
Jerry Barbato
executiveNow moving to the U.S. business, net revenue for the first quarter of 2021 came in at $2.4 million, which was up 12% compared with the same period a year earlier. The year-over-year top-line improvement was mainly the result of launching new hemp-derived CBD products. Gross profit in the U.S. segment during the first quarter of 2021 reached $1.2 million, an increase of $100,000 over the first quarter of 2020. The adjusted EBITDA loss for the U.S. segment in the first quarter of 2021 totaled $9.5 million, which reflects $3.7 million more in losses than in the first quarter of 2020. Those larger losses were chiefly the result of higher sales and marketing expenses tied to brand development. On the whole, Cronos Group posted a decline in net income relative to the prior year period, largely because of the change in fair value of the financial derivative liabilities connected to Altria's investment, which the 10-Q describes in greater detail. During the first quarter of 2021, the company recorded a non-cash loss of $116.9 million tied to the change in fair value of those financial derivative liabilities. Cronos still anticipates that reported earnings may experience significant volatility, mainly as a result of the quarterly fair value adjustments driven by movements in Cronos Group's stock price.
Jerry Barbato
executiveNow looking at our balance sheet: we closed the quarter with about CAD 1.2 billion in cash and short-term investments, a decrease of roughly CAD 50 million compared with the fourth quarter of 2020. For the quarter, capital expenditures came to CAD 7.1 million, and that spending was concentrated across our global strategic priorities. Our commitment to deploying capital with discipline remains firm, and we will do so only in ways that fit our strategic priorities. The work our teams are carrying out around the world continues to encourage me. With that, I'll hand things to Kurt for closing remarks ahead of Q&A.
Kurt Schmidt
executiveThanks, Jerry. During this quarter, we kept carrying out our strategy and achieved growth even with the pandemic's continuing effects, and we're hugely energized about sustaining that momentum across the whole company. Concentrating on backing our regional strategies and backing our R&D and innovation efforts at the brand level, we keep advancing with inventive products and distinctive marketing campaigns. So with that, let's open the line for questions now.
Operator
operatorThanks. If you’d like to ask something, press star one on your phone. If you want to take your question back, hit the pound or hash key. Everyone gets one question plus one follow-up. Please hold while we put together the Q&A list. Our first question is from Rahul Sarugaser at Raymond James.
Rahul Sarugaser
analystMorning, Kurt, Mike, and Jerry. We appreciate you taking our questions. My first one centers mainly on biosynthesis. Kurt, you called that out as a major milestone, in particular the Health Canada license, which was of course significant. When you say research scale of CBG, what exactly does that mean? What scale are you aiming to reach? Which cannabinoids should we expect to see next, and what are the timelines for getting those cannabinoids into your commercial products?
Kurt Schmidt
executiveThanks for asking that. Obviously, we're shifting from a small R&D pilot scale. We're now moving into the Winnipeg facility so we can produce at scale, and that will let us launch products into the Canadian market starting with a first molecule, which is CBG, correct, as you said. Then we're looking at the sequential next — as we've said before, we have roughly 7 separate molecules in development with Ginkgo, and they'll roll out sequentially over time as we move forward. CBG is the first. We also mentioned that our focus will be on the rare cannabinoids to begin with, because we feel that's the most interesting part of the product line, the most differentiation and value-added products we can bring to consumers. We want to focus on those first versus the major cannabinoids of CBD and THC.
Rahul Sarugaser
analystGreat, thank you very much, Kurt. So maybe my follow-up question is this: since Cronos is, as far as we know, the sole cannabis business possessing its own fermentation capabilities and producing these products from them, how do you view that as a competitive edge—something of a unique position within the sector—and also as a capability you can translate as you continue building out your U.S. sales infrastructure?
Kurt Schmidt
executiveYes. There are a few points. First, clearly, through developing this capability at our Winnipeg facility, we are gaining the knowledge required for large-scale output of these items — for large-scale cannabinoid production — and that matters a great deal. It is the production know-how that complements our innovation know-how. Naturally, Canada has long served us as a development base for possibly entering the U.S. with certain of these products. Do you want to add anything to that.
Mike Gorenstein
executiveThanks. Yeah, I would just add that a key thing we're enthusiastic about right now, now that we can begin ramping up in Winnipeg, is our goal of getting these products containing rare cannabinoids launched early and fast in Canada, so we can observe how they do and gain learnings. Considering the timeline we anticipate in the U.S., we'll be in a position to launch these products with plenty of information in the U.S. market once we're able to access it, with expected federal permissibility arriving in the near future.
Rahul Sarugaser
analystThat's great, and congratulations on the progress. Thanks for taking our question. We'll rejoin the queue.
Operator
operatorThe next question is from John Zamparo at CIBC.
John Zamparo
analystThanks. Morning, everyone. My question is on gross margins — specifically how they'll trend across the rest of world segments over the coming year or so, and really what it takes to bring them nearer to where most of your peers sit. Is it simply that you need a certain minimum sales threshold to cover fixed costs, or does some piece of forward purchasing commitments have to roll off as well? Any color you can give would be appreciated.
Jerry Barbato
executiveYes, thank you, John. We will continue to see gross margin move around as pricing and mix shift from one quarter to the next. Those mix shifts reflect not just the product mix but also how revenue is split between Canada and Israel. As you mentioned in your question, our Q1 margins took a bit of a hit as revenue decelerated sequentially, and our cost structure is heavily fixed because of the Stayner facility. We expect those pressures to lessen over time as our revenue base expands, our manufacturing and purchasing teams improve processes, and prices settle down, both in the wholesale market and on the shelf.
John Zamparo
analystAlright, thank you. My next question concerns M&A. There has been a fairly clear uptick in M&A activity within Canada. I’m wondering whether your thinking has shifted in any way, such that you would now consider any Canadian assets, and how should we view the U.S. M&A approach ahead of any movement toward legalization?
Kurt Schmidt
executiveThanks, John, for raising that. Mike will chime in on this as well. As for Canada, we intend to apply the very same discipline we've maintained throughout, meaning that, first, between our innovation efforts and the brands we currently own, we believe we have a fairly solid handle on the portfolio. That said, it doesn't mean we wouldn't examine opportunities. We'll bring the same sort of discipline to bear that we've applied to everything in this space previously. At this moment I feel quite comfortable. Our approach has consistently been to build out our own brands. We have our Canadian portfolio. We also hold brands in the U.S., and you'll probably see some combination of possible M&A, but I'd like Mike to offer his perspective here, since a lot of his attention over the past year has gone into this.
Mike Gorenstein
executiveAppreciate that, Kurt, and thank you, John. Yes, you've got it exactly. Our view is that in the U.S. we're nearer to a point where we can run things directly ourselves, and we're confident there are routes available to us that give us optionality in the near term. At the same time, we'll keep making certain they can deliver as we step in actively on our own.
John Zamparo
analystAll right, that clears things up nicely. Thanks a lot.
Operator
operatorAndrew Carter from Stifel has the next question in the queue.
Andrew Carter
analystHey, thanks, and good morning. I'd like to ask about the edibles rollout in Canada. Clearly, that market offers a federally legal framework for testing and developing products, but how do you balance obtaining truly accurate consumer insights given the marketing restrictions as well as the limits on packaging? Could you discuss the price point you're launching at as well as the forms, and will you go beyond Spinach? Thanks.
Kurt Schmidt
executiveAppreciate that, Andrew. To start, this edible launch has us genuinely excited, since I think the product itself could hold its own against any confectionery item out there in the non-THC space. It's truly an innovative offering, and it's really unique in the marketplace. We think that's terrific. As for whether it's applicable — not to everything, because clearly, if you look at the U.S., the regulatory environment, broadly speaking, resembles alcohol more than it resembles the pharma-style regulatory environment in Canada. There are lessons we pick up — consumer acceptance, concept. We have remarkable research capabilities and consumer insights, and we bring those to bear on the U.S. We examine Canadian consumers the same way we examine those in the U.S., so it's highly applicable. That's part of the beauty of what we're doing. It lets us test those ideas and concepts and be ready and move quickly when, as Mike mentioned earlier, federal legalization arrives. We think it's very applicable. Sure, you have to factor in a bit of dimensionality given that the U.S. will be a larger opportunity. It's not only the market's size, but the market's stability too.
Kurt Schmidt
executiveRegarding the U.S. side of things, the Canadian testing platform is quite significant, and through our capabilities we are already gaining knowledge on how to bring those lessons into the American market.
Mike Gorenstein
executiveSecond, just to add—sorry, Andrew, let me add to that. There's one thing here that's really important to bring back up: from a learning perspective, it's really helpful for us to have product formats, so that when we introduce rare cannabinoids and differentiated products, we think those learnings are applicable from a formulation perspective—what kind of feedback. It might not cover all the brand elements and the marketing plan, but on the actual product itself and having a breakthrough product, we think we'll still be able to get that information.
Andrew Carter
analystThanks. For my second question, I'd like to follow up on gross margin, but more broadly, could you give us some idea of what you expect regarding timing — when the worldwide supply chain and all those tailwinds will really take effect and fully serve the needs of the business? In other words, when will GrowCo reach full scale so that it can support the Canadian operation as well as the domestic Israel business completely? Thank you.
Kurt Schmidt
executiveYes. It's Kurt here. I'll get us started, and Jerry might have a few points to add. Regarding GrowCo, once more, our thinking has been that biomass is going to grow more commoditized, and the big agricultural growers will be the major participants here. We're genuinely happy to see how this partnership involving GrowCo and Mucci is progressing. The project is now up and running with the required licenses, and the fact that we just obtained the processing license means we can sell into the wholesale market as of now. You'll see it come online in stages across the first half of this year, and harvesting is part of that. We won't talk about any of the KPIs tied to it, but we're in the early innings. I'll say that we're pleased with how it's developing, and with what Mucci brings to this endeavor. We're on track, and we feel good about it.
Mike Gorenstein
executiveAlright.
Andrew Carter
analystTurning now to Israel alone?
Kurt Schmidt
executiveAlright.
Jerry Barbato
executiveI’d like to add a small point here. Israel, you’re correct — we’re very pleased with the Q1 performance. The Cronos Israel team has accomplished a great deal in such a short period. As that medical market grows, clearly we faced headwinds that Kurt discussed in the prepared remarks. The patterns we’re observing during COVID in Canada — with consumers either under lockdown or generally moving around less — are that their preferences have changed, and you’ve seen provinces place fewer orders and reduce their inventory levels. I think all of that affects margin, because as you noted, you have to keep expanding that revenue base so those fixed costs can be absorbed.
Andrew Carter
analystAppreciate that. I'll make sure it gets to the right people.
Operator
operatorJust a quick reminder — if you’d like to ask a question, please press star one on your phone’s keypad. Everyone gets one question and one follow-up. Our next question is from Heather Balsky at Bank of America.
Heather Balsky
analystHi, thanks for taking my questions. So, first off, on the CBD product that you're launching, how are you approaching your go-to-market strategy, particularly when it comes to the learning curve for customers and budtenders regarding the product? And then, as you roll out the product, how are you thinking about eventually educating U.S. consumers in a less restrictive environment? Thanks.
Kurt Schmidt
executiveYes. Well, launching this product in Canada and figuring out how we talk about it in the retail sector is all part of the learning there. All of that sits within the planning of the works, and much of it will carry over to the U.S. Some of it won't, since the U.S. has a different marketing environment. At the moment we feel we're getting all those plans in place and, as we said earlier, it's going to be the third quarter of this year, and alongside getting the product ready, we're working on the marketing program as well.
Heather Balsky
analystAppreciate it. Moving on to my follow-up question—
Kurt Schmidt
executiveRegarding Canada, that situation will persist. The U.S. and Israel, in my view, are markets that sit further along, where the vaccine's large effect is visible. That element is essential as well, I believe. As you observe the vaccines being distributed across the U.S., regions such as the Northeast and California have suffered more severely, have imposed tighter restrictions, closer to what Canada faces. We're watching brick-and-mortar locations reopen. When those brick-and-mortar locations reopen, consumers begin venturing out again. Weather adds to that, since cold conditions clearly play a role. All of these elements—say, sporting events resume, brick-and-mortar locations resume—you begin to witness a relative return toward normalcy and forward movement. It will still require some time, but my confidence is high. We monitor the vaccination rate as a statistic that matters greatly to us, and I consider it significant going forward, especially for Canada.
Heather Balsky
analystExcellent. I really appreciate it.
Operator
operatorThat brings us to the end of the audio questions. Would anyone like to offer closing remarks?
Kurt Schmidt
executiveNo, there isn’t.
Operator
operatorThank you. That brings us to the end of today's conference call, ladies and gentlemen. We appreciate everyone for joining in. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.